Empty AAV capsids induce immune response without therapeutic benefit
Empty AAV capsids lacking the transgene of interest cause an unwanted immune response without providing the therapeutic benefit of the transgene. Alongside DNA and infectious titers, determination of the capsid titer is crucial for validating the efficacy and safety of your AAV gene therapy. Our titration kits detect full and empty AAV capsids.
As the gene therapy market using adeno-associated virus (AAV) as a vector continues to rapidly develop, regulatory agencies have imposed increasingly stringent requirements for quality control (QC) testing of AAV drugs. To ensure the safety and efficacy of AAV drugs, there is a need for effective, reliable, and stable methods to quantify AAV viral particle titers.